Also, when we examined the effect of ML364 on diverse cancer cell lines (renal carcinoma, ACHN; prostate carcinoma, DU145; and lung carcinoma, A549), all tested cells showed survivin downregulation in ML364 treatment (Figure 1B). Here, BIRC5 is linked to prostate carcinoma.